The tremendous amount of information in the endpoints library served as a rich resource to feed DEEP’s catalog.

— Bert Hartog, Co-founder of DEEP and Senior Director, Janssen Clinical Innovation

The Opportunity

» In digital measures development there is a historic lack of harmonization and cumbersome regulatory acceptance pathways, in part due to a lack of transparency.

» The DEEP initiative aims to centralize and standardize digital measure development efforts, encouraging fit-for-purpose solutions.

The Impact

» DEEP expanded on DiMe's library by integrating the data from the library into a newly developed catalog.

» In the catalog DEEP layers on additional content, including use cases and evidence data to enrich the value of the endpoint library's data.

» This catalog is one component of DEEP’s holistic solution, which enables more effective digital clinical measurement usage.

Janssen is the pharmaceutical company of J&J focused on Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Arterial Hypertension diseases. Digital Endpoints Ecosystem and Protocols (DEEP), a Janssen initiative, was founded to facilitate the development of novel clinical endpoints for clinical trials.

Leaders from the DEEP initiative leveraged DiMe’s Library of Digital Endpoints to:

1. Understand how and at what scale sponsors were already using digital endpoints
2. Validate the DEEP’s assumptions and hypotheses
3. Identify opportunities to standardize digital endpoints

The Resources